text: Modafinil was considered for the treatment of ADHD because of its lower abuse potential than conventional psychostimulants like methylphenidate and amphetamines. In 2008, an application to market modafinil for pediatric ADHD was submitted to the Food and Drug Administration in the US.
  However, evidence of modafinil for treatment of adult ADHD is mixed, and a 2016 systematic review of alternative drug therapies for adult ADHD did not recommend its use in this context. In a later large phase 3 clinical trial of modafinil for adult ADHD, modafinil was not effective in improving symptoms, and there was a high rate of side effects (86%) and discontinuation (47%). The poor tolerability of modafinil in this study was possibly due to the use of high doses (). Another reason for the denial of the approval was due to concerns about rare but serious dermatological toxicity in Stevens–Johnson syndrome).